{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:54:52Z","timestamp":1789167292144,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T00:00:00Z","timestamp":1547078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck Sharp & Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck Sharp & Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ijantimicag.2019.01.006","type":"journal-article","created":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T09:36:02Z","timestamp":1547199362000},"page":"325-329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Posaconazole trough concentrations are not influenced by inflammation: A prospective study"],"prefix":"10.1016","volume":"53","author":[{"given":"Anne-Grete","family":"M\u00e4rtson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anette","family":"Veringa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martijn","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin R.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1429-4789","authenticated-orcid":false,"given":"Daan J.","family":"Touw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjip S.","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lambert F.R.","family":"Span","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0288","authenticated-orcid":false,"given":"Jan-Willem","family":"C. Alffenaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0001","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0002","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s12281-016-0255-4","article-title":"Therapeutic drug monitoring of posaconazole: an update","volume":"10","author":"Dekkers","year":"2016","journal-title":"Curr Fungal Infect Rep"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0003","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/FTD.0000000000000235","article-title":"Subtherapeutic posaconazole exposure and treatment outcome in patients with invasive fungal disease","volume":"37","author":"van der Elst","year":"2015","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0004","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1128\/AAC.03777-14","article-title":"Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis","volume":"58","author":"Dolton","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0005","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0006","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1086\/597110","article-title":"Omeprazole significantly reduces posaconazole serum trough level","volume":"48","author":"Alffenaar","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0007","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1128\/AAC.00802-12","article-title":"Multicenter study of posaconazole therapeutic drug monitoring: exposure\u2013response relationship and factors affecting concentration","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0008","doi-asserted-by":"crossref","first-page":"6298","DOI":"10.1128\/AAC.01177-12","article-title":"Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome","volume":"56","author":"Vaes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0009","doi-asserted-by":"crossref","first-page":"5247","DOI":"10.1128\/AAC.00815-12","article-title":"Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease","volume":"56","author":"Tonini","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0010","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1128\/AAC.02686-13","article-title":"Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease","volume":"58","author":"Maertens","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0011","doi-asserted-by":"crossref","first-page":"4020","DOI":"10.1128\/AAC.02448-13","article-title":"Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects","volume":"58","author":"Kraft","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0012","doi-asserted-by":"crossref","first-page":"7098","DOI":"10.1128\/AAC.03820-14","article-title":"Inflammation is associated with voriconazole trough concentrations","volume":"58","author":"van Wanrooy","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0013","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1128\/AAC.04789-14","article-title":"Influence of inflammation on voriconazole metabolism","volume":"59","author":"Encalada Ventura","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0014","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jac\/dkw349","article-title":"Voriconazole metabolism is influenced by severe inflammation: a prospective study","volume":"72","author":"Veringa","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0015","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1586\/14787210.3.4.467","article-title":"Posaconazole: clinical pharmacology and potential for management of fungal infections","volume":"3","author":"Groll","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0016","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0017","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1124\/dmd.32.2.267","article-title":"Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)","volume":"32","author":"Ghosal","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0018","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1006\/taap.1996.0077","article-title":"Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes","volume":"137","author":"Monshouwer","year":"1996","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0019","series-title":"Noxafil (posaconazole)\u2014summary of product characteristics","author":"Sharp","year":"2017"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jchromb.2009.11.017","article-title":"Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC\/MS\/MS","volume":"878","author":"Alffenaar","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0021","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1093\/jac\/dku242","article-title":"Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations","volume":"69","author":"Lempers","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0022","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.48.9.3543-3551.2004","article-title":"Disposition of posaconazole following single-dose oral administration in healthy subjects","volume":"48","author":"Krieter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0023","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/dmd.30.2.129","article-title":"UDP glucuronosyltransferase mRNA levels in human liver disease","volume":"30","author":"Congiu","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0024","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.bbi.2018.02.013","article-title":"Rethinking IL-6 and CRP: why they are more than inflammatory biomarkers, and why it matters","volume":"70","author":"Del Giudice","year":"2018","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0025","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.drudis.2014.11.010","article-title":"Challenges regarding analysis of unbound fraction of highly bound protein antiretroviral drugs in several biological matrices: lack of harmonisation and guidelines","volume":"20","author":"Illamola","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0026","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.trac.2015.11.026","article-title":"LC-MS\/MS for therapeutic drug monitoring of anti-infective drugs","volume":"84","author":"Veringa","year":"2016","journal-title":"TrAC Trends Anal Chem"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0027","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.clinbiochem.2018.01.004","article-title":"Simultaneous determination of voriconazole, posaconazole, itraconazole and hydroxy-itraconazole in human plasma using LCMS\/MS","volume":"53","author":"Jenkins","year":"2018","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0028","doi-asserted-by":"crossref","first-page":"5074","DOI":"10.1128\/AAC.00022-10","article-title":"Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing","volume":"54","author":"Rochat","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.01.006_bib0029","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1093\/jac\/dkx440","article-title":"Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations","volume":"73","author":"Jeong","year":"2018","journal-title":"J Antimicrob Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919300068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919300068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:32:56Z","timestamp":1760376776000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919300068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0924857919300068"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.01.006","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posaconazole trough concentrations are not influenced by inflammation: A prospective study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}